Vaccinology Theme, Medical Research Council Unit, Banjul, The Gambia.
Vaccine. 2012 Aug 17;30(38):5591-4. doi: 10.1016/j.vaccine.2012.06.054. Epub 2012 Jun 27.
This study aimed to evaluate the durability of the immunogenicity of MVA85A beyond infancy. Participants in an immunogenicity study of MVA85A administered at age of 4 months had additional evaluation 14 months after initial vaccination for IFN-γ ELISPOT responses to Ag85A peptide and ESAT6/CFP-10 and tuberculin skin test (TST). 112 children participated in this study. The anthropometry, biochemical and haematological safety profile were similar between the MVA85A recipients and controls. MVA85A recipients still had significantly higher immune responses to Ag85A compared to the controls. The majority of these children had negative responses to the TST as well as the ESAT6/CFP-10 antigens. In summary, MVA85A-vaccinated children had a persistently higher Ag85A immune response 14 months following vaccination than controls. All the children had negligible evidence of latent infection with M. tuberculosis (Mtb), suggesting that deploying a prophylactic vaccine against Mtb infection at this age could still be effective in this setting.
本研究旨在评估 MVA85A 在婴儿期后的免疫原性持久性。在 4 个月大时接种 MVA85A 的免疫原性研究参与者，在初次接种后 14 个月，对 Ag85A 肽、ESAT6/CFP-10 和结核菌素皮肤试验（TST）的 IFN-γ ELISPOT 反应进行了额外评估。112 名儿童参与了这项研究。MVA85A 受种者和对照组的人体测量、生化和血液学安全性特征相似。与对照组相比，MVA85A 受种者对 Ag85A 的免疫反应仍显著更高。这些孩子中的大多数对 TST 以及 ESAT6/CFP-10 抗原的反应均为阴性。总之，接种 MVA85A 的儿童在接种后 14 个月时对 Ag85A 的免疫反应仍持续高于对照组。所有儿童均有证据表明对结核分枝杆菌（Mtb）的潜伏感染可忽略不计，这表明在这个年龄段使用预防性疫苗来预防 Mtb 感染在这种情况下仍然可能有效。
